Key result
Multiple myeloma-related CD34+ progenitor cells expressed significantly lower levels of RENIN and ANGTS mRNA compared to normal CD34+ hematopoietic stem cells.
Observational (n=28)
No
Answers are grounded in this paper and cite their sources.
No immediate change to RAS inhibitor use in MM; leaves open progenitor cell dysfunction as a disease mechanism.
OBJECTIVE: The prominent functions of the local renin-angiotensin system (RAS) in primitive hematopoiesis further support the hypothesis that local autocrine bone marrow RAS could also be active in neoplastic hematopoiesis. The aim of this study is to examine critical RAS elements in normal CD34+ hematopoietic stem cells and multiple myeloma (MM)-related progenitor cells. MATERIALS AND METHODS: The study group comprised the total bone marrow cells (CBM) of 10 hematologically normal people, the CD34+ stem cell samples (CD34+CBM) of 9 healthy donors for allogeneic peripheral stem cell transplantation, and the CD34+ stem cell samples (CD34+MM) of 9 MM patients undergoing autologous peripheral stem cell transplantation. We searched for the gene expression of the major RAS components in healthy hematopoietic cells and myeloma cells by quantitative real-time polymerase chain reaction analysis. RESULTS: RENIN, angiotensinogen (ANGTS), and angiotensin converting enzyme-I (ACE I) mRNA expression levels of CBM were significantly higher than those in myeloma patients (p=0.03, p=0.002, and p=0.0008, respectively). Moreover, RENIN and ANGTS mRNA expression levels were significantly higher in CD34+ stem cell samples of healthy allogeneic donors compared to those in myeloma patients (p=0.001 and p=0.01). However, ACE I expression levels were similar in CD34+CBM and CD34+MM hematopoietic cells (p=0.89). CONCLUSION: Although found to be lower than in the CBM and CD34+CBM hematopoietic cells, the local RAS components were also expressed in CD34+MM hematopoietic cells. This point should be kept in mind while focusing on the immunobiology of MM and the processing of autologous cells during the formation of transplantation treatment protocols.
No takes yet. Share an insight, caveat, or question.
Uz et al. (2014) conducted an observational in Multiple Myeloma (n=28). Multiple Myeloma (CD34+MM cells) vs. Healthy donor CD34+ cells (CD34+CBM) was evaluated on Relative RENIN mRNA expression (p=0.03). Multiple myeloma-related CD34+ progenitor cells expressed significantly lower levels of RENIN and ANGTS mRNA compared to normal CD34+ hematopoietic stem cells.
Synapse has enriched 10 related papers. Consider them for comparative context: